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Abstract
Introduction: Our objective was to compare the bone and renal effects among HIV-infected patients randomized to
abacavir or tenofovir-based combination anti-retroviral therapy.
Methods: In an open-label randomized trial, HIV-infected patients were randomized to switch from zidovudine/lamivudine
(AZT/3TC) to abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC). We measured bone mass density (BMD)
and bone turnover biomarkers (osteocalcin, osteocalcin, procollagen type 1 N-terminal propeptide (P1NP), alkaline
phosphatase, type I collagen cross-linked C-telopeptide (CTx), and osteoprotegerin). We assessed renal function by
estimated creatinine clearance, plasma cystatin C, and urinary levels of creatinine, albumin, cystatin C, and neutrophil
gelatinase-associated lipocalin (NGAL). The changes from baseline in BMD and renal and bone biomarkers were compared
across study arms.
Results: Of 40 included patients, 35 completed 48 weeks of randomized therapy and follow up. BMD was measured in 33,
26, and 27 patients at baseline, week 24, and week 48, respectively. In TDF/FTC-treated patients we observed significant
reductions from baseline in hip and lumbar spine BMD at week 24 (21.8% and 22.5%) and week 48 (22.1% and 22.1%),
whereas BMD was stable in patients in the ABC/3TC arm. The changes from baseline in BMD were significantly different
between study arms. All bone turnover biomarkers except osteoprotegerin increased in the TDF/FTC arm compared with
the ABC/3TC arm, but early changes did not predict subsequent loss of BMD. Renal function parameters were similar
between study arms although a small increase in NGAL was detected among TDF-treated patients.
Conclusion: Switching to TDF/FTC-based therapy led to decreases in BMD and increases in bone turnover markers
compared with ABC/3TC-based treatment. No major difference in renal function was observed.
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Introduction
Highly active anti-retroviral therapy (HAART) has substantially
reduced mortality and morbidity from human immunodeficiency
virus (HIV) infection. With effective HAART HIV-infected
patients have a life expectancy approaching that of the general
population [1], but are faced with life-long treatment. Under-
standing the long-term consequences, including bone and renal
effects, of HIV-infection and anti-retroviral exposure is therefore
of increasing importance.
At the initiation of this study fixed-dose combinations of
tenofovir (TDF)/emtricitabine (FTC) or abacavir (ABC)/lamivu-
dine (3TC) were recommended for initial treatment of HIV
infection [2,3]; TDF/FTC was later recommended over ABC/
3TC in some guidelines [4].
Previous studies have indicated an increased prevalence of
osteopenia and osteoporosis [5], as well as increased rates of
fractures [6], among HIV-infected individuals compared to HIV-
uninfected controls, but the relative contribution to this of HIV-
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factors is still not completely resolved. Results from several
randomized clinical trials among anti-retroviral naı ¨ve patients
have shown that initiation of HAART is associated with a decrease
in bone mineral density (BMD) of 2%–6% at both the hip and
spine that occurs within the first year of treatment with
stabilization thereafter [7–13]. Of these, two trials directly
compared TDF/FTC with ABC/3TC and both found greater
decreases in BMD with TDF/FTC-based treatment than with
ABC/3TC-based treatment [11,13]. To date, only one trial has
reported on BMD among virologically suppressed HIV-infected
patients switching to TDF/FTC or ABC/3TC-based treatment.
In this study, patients randomized to TDF/FTC experienced
decreases in BMD compared with ABC/3TC as measured by dual
energy x-ray absorptiometry (DXA) [14].
Case reports of renal dysfunction associated with TDF therapy
[15,16] raised concerns of a nephrotoxic effect with this
compound, but the incidence of adverse renal effects were low
in initial randomized trials and comparable to thymidine
analogues [7,17]. In a recent meta-analytic review of prospective
studies comparing TDF-containing with non-TDF containing
HAART-regimes a small but statistical significant loss of renal
function was associated with TDF use [18]. Included herein are 3
studies comparing TDF with ABC with mixed results on the renal
endpoints [19–21]. In addition, there was no difference in
estimated glomerular filtration rate (GFR) between patients
randomized to ABC- or TDF-based therapy in the STEAL [14]
or ASSERT-study [22], but increases in markers of proximal
tubule dysfunction were observed in the TDF-arm of the latter.
Some of the discrepancy is likely related to differences in selection
criteria for study participants with regard to renal function.
The Efficacy and Safety of Switching from Zidovudine to
Tenofovir or Abacavir in HIV-infected Patients (SWAP) study was
a randomized trial comparing switching from zidovudine (AZT)/
3TC to ABC/3TC or TDF/FTC. We have previously published a
report on cardiovascular biomarkers from this trial [23] and here
provide the main results from the trial. The aims of this study were
to compare the effects of abacavir and tenofovir on renal function
and bone mass density, including exploratory analyses of several
biomarkers of bone turnover and renal dysfunction.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study participants
The SWAP study was an open-label, parallel-group, random-
ized clinical trial assessing the safety and efficacy of switching from
AZT to ABC- or TDF-based therapy. The study design and
patient group have been described previously [23]. In brief,
eligible patients had documented HIV-infection and, for at least 3
months, had been treated with HAART comprising AZT and had
undetectable plasma HIV-RNA. The pre-specified primary end-
points were renal function assessed by cystatin C (cysC), creatinine
clearance (CrCl) and markers of tubule function; bone mass
density and bone metabolism assessed by DXA and bone turnover
markers; lipodystrophy and body composition assessed by DXA
and patient questionnaire; and insulin sensitivity. A sample size of
90 participants was estimated as being required to detect
differences in the renal tubular function at a 5% significance level
based on existing limited knowledge on the frequency of impaired
tubular function with tenofovir and abacavir based therapy.
Patients who had previously used ABC or TDF, had diabetes
mellitus, untreated hypertension, renal disease, osteoporosis or
who were positive for the HLAB5701 allele upon screening were
excluded. Informed written consent was obtained before enrol-
ment. At baseline, patients were stratified after use of protease
inhibitors and randomized 1:1 to switch from AZT to ABC
600 mg or TDF 300 mg daily using sequentially numbered
envelopes generated by the Aarhus University Hospital Pharmacy.
The treating physician assigned patients to intervention. If
lamivudine (3TC) or emtricitabine (FTC) was given as part of
HAART at inclusion, patients were randomized to a fixed-dose
treatment with ABC/3TC 600/300 mg or TDF/FTC 300/
200 mg daily. The study took place at the Department of
Infectious Diseases, Aarhus University Hospital, Skejby, Denmark.
Patients were followed up at 4, 8, 12, 24, and 48 weeks after
randomization. A pre-planned follow up at 96 weeks was not
performed because the study was discontinued in November 2009
before reaching the intended number of study participants. For
this reason, and lack of funding, final analyses were restricted to
bone, renal, and cardiovascular investigations. No interim analyses
were planned and none was performed before recruitment was
stopped. The study was approved by the Regional Research Ethics
Committee, Central Denmark Region (Journal number: M-
20070189; Eudract. number: 2007-004372-39) and conducted in
accordance with Good Clinical Practice. Anthropometric information
and data on age, sex, smoking habits, blood pressure, CD4+ cell
counts, viral load, and duration of HIV-infection and HAART
exposure were retrieved from the study database or patient
records.
BMD and biomarkers of bone turnover
DXA scans (DXA machine Hologic Discovery A (S/N 82962))
of the lumbar spine and hip were performed at baseline, week 24
and 48 at The Department of Endocrinology and Internal
Medicine, Aarhus University Hospital, Denmark. Serum and
plasma samples were collected at baseline and week 4, 12, 24, and
48. Samples were stored at 280uC until analyses. We measured 2
biomarkers of bone formation, osteocalcin (OC) and procollagen
type 1 N-terminal propeptide (P1NP;) [24,25] in plasma at
baseline and week 4, 12, and 48 (both with a luminometric assay
on Cobas 6000E, Hoffmann-La Roche; OC reference range 10–
53 mg/L for women and 13–77 mg/L for men; P1NP reference
range ,62 mg/L for premenopausal women, ,93 mg/L for
postmenopausal women, and 20–76 mg/L for men). Plasma
alkaline phosphatase levels were measured by a micro slide assay
(Vitros FS 5.1, Ortho-clinical Diagnostics, reference range 35–
105 U/L) at baseline and week 4, 12, 24, and 48. Plasma levels of
type I collagen cross-linked C-telopeptide (CTx), a biomarker of
bone resorption [24,25], and osteoprotegerin (OPG) that is
competitive inhibitor of osteoclast activation and differentiation
[25–27], were measured at baseline and week 4, 12, and 48. CTx
was measured using a luminometric assay on Elecsys 2010
(Hoffmann-La Roche) (reference range 0.04–0.87 mg/L for men
,70 years, 0.04–0.87 mg/L for premenopausal women, and 0.03–
0.83 mg/L for postmenopausal women) and OPG was assayed by
a commercially available enzyme-linked immunosorbent assay
(ELISA) (reference range 0.6–6.9 pmol/L) as described by the
manufacturer (Biomedica Gruppe, Vienna, Austria). Baseline
levels of 25-OH D2/D3 vitamin D in serum were determined
using a mass spectrometry assay (reference range 50–160 nmol/
L). Previous plasma measurements of interleukin-6 (IL-6) and high
sensitive C-reactive protein (hs-CRP) [23] were used to assess
concurrent inflammation at baseline. All biomarkers were batch-
tested.
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Twenty-four hour urine collection was done at baseline and
week 12, 24, and 48, but was incomplete or omitted in several
patients at various time points. Instead, we measured plasma
creatinine and phosphate levels at baseline and week 4, 8, 12, 24,
and 48 (Vitros FS 5.1 Ortho-clinical Diagnostics) and used the
Cockcroft-Gault formula to estimate creatinine clearance (eCrCl).
Plasma cysC was measured at baseline and week 48. In addition,
we determined urinary levels of creatinine, albumin, cysC, and
neutrophil gelatinase-associated lipocalin (NGAL) among patients
with urine samples from at least 2 time points and used the ratios
of albumin, cysC, and NGAL levels relative to urine creatinine
concentration to identify signs of renal dysfunction. The change in
ratio from baseline to the second measurement was compared
across study arms regardless of which time the latter was
performed. Plasma and urinary cysC was determined by a particle
enhanced nephelometric assay using the N Latex cysC assay on
the Behring Nephelometer II (Siemens Healthcare Diagnostics
Products GmbH, Marburg, Germany) as described previously
[28]; reference level for plasma cysC is 0.51–1.02 mg/L [29].
Urinary NGAL concentration was determined using a commercial
ELISA assay (Bioporto). Urinary albumin was assayed on the
Behring Nephelometer II (Siemens Healthcare Diagnostics
Products GmbH, Marburg, Germany) and urinary creatinine
was assayed using the Roche Modular Analytics P automated
clinical analyzer (Roche Diagnostics, Mannheim, Germany).
Statistics
Baseline data were compared using x
2-test for categorical
variables and two-sample t-test or Wilcoxon rank sum test for
continuous variables. Percentage changes from baseline to week 24
and 48 in total hip and lumbar spine BMD were computed and
compared within and between study arms using one- and two-
sample t-tests, respectively. The changes from baseline to the
various time points in levels of bone and renal biomarkers were
compared between study arms using two-sample t-test or
Wilcoxon rank sum test, as appropriate. Data distribution was
assessed through visual inspection of frequency histograms and
normal probability plots; logarithmic transformation was explored
on skewed data to allow parametric hypothesis testing whenever
possible. Linear regression was used to explore whether changes in
bone turnover biomarkers at early time points (baseline to week 4
and 12, respectively) predicted subsequent reductions in BMD at
week 48. Statistical analyses were per-protocol as pre-specified in
the study protocol. P-values,0.05 were considered statistically
significant. Stata 10 was used for statistical analyses.
Results
Study participants
Details of study treatment and the patient group have been
described previously [23]. Because of uncertainty about ABC as an
appropriate first-line treatment option, patient inclusion was
suspended in January 2009 and finally terminated in August
2009. By this time 40 patients had been enrolled (20 in each arm).
Of these, 35 completed 48 weeks of therapy and follow-up (20 in
the TDF/FTC arm and 15 in the ABC/3TC arm). The flow of
patient inclusion and follow-up is illustrated in Fig. 1. Two patients
in the ABC/3TC arm were excluded shortly after randomization
and contribute only to baseline data. One patient was excluded
because of an allergic skin reaction upon starting ABC therapy (the
patient was tested negative for the HLAB5701 allele), and one
patient was excluded because of alcohol abuse and poor adherence
to study drugs. Three patients in the ABC/3TC arm were
excluded at week 12 for the following reasons: initiated treatment
for hepatitis C, intention of pregnancy, and a history of diabetes
mellitus, respectively. The latter patient had a history of diabetes
prior to randomization and was listed as a screening failure. All 3
patients contributed data up to and including week 12. The
remaining 35 study subjects all completed 48 weeks of therapy and
follow-up. One patient (TDF/FTC arm) did not provide the week-
4 blood sample. One serious adverse event was reported during
the study; this was a resolved episode of pyelonephritis in a patient
with a history of recurrent urinary tract infections. Five grade 2
adverse advents were registered (4 in the ABC/3TC arm and 1 in
the TDF/FTC arm), but none necessitated discontinuation of
study drugs. No grade 3 or 4 adverse advents were reported.
None of the study participants received systemic corticosteroids,
bisphosphonates, vitamin D, calcium or other therapies known to
affect bone metabolism at enrolment or during the study. Baseline
characteristics of the patients are shown in Table 1, including
baseline levels of bone and renal biomarkers. Levels of P1NP were
higher among patients in the ABC/3TC arm than the TDF/FTC
arm (P=0.040), but no other baseline parameter differed
significantly between treatment groups, including levels of the
inflammatory biomarkers, hs-CRP and IL-6.
BMD and biomarkers of bone turnover
As DXA scan could not be conducted in all patients, changes
from baseline in BMD was only evaluated for 26 (16 TDF/FTC
arm and 10 ABC/3TC arm) and 27 (15 TDF/FTC arm and 12
ABC/3TC arm) patients at week 24 and 48, respectively. In 7
cases (4 TDF/FTC arm and 3 ABC/3TC arm) the week 4
measurements of OPG was omitted due to lack of plasma.
We observed significant reductions from baseline in both hip
and lumbar spine BMD at week 24 and 48 among TDF/FTC-
treated patients, whereas BMD was stable in patients in the ABC/
3TC arm. The mean percentage change at week 24 in hip and
lumbar spine BMD was 21.8% (95% CI 22.6 to 21.1; P,0.001)
and 22.5% (95% confidence interval (CI) 23.7 to 21.3;
P,0.001) in the TDF/FTC arm compared to 0.1% (95% CI
21.1 to 1.2; P=0.894) and 20.3% (95% CI 22.1 to 1.4;
P=0.671) in the ABC/3TC arm. At week 48 the mean percentage
change in hip and lumbar spine BMD was 22.1% (95% CI 23.4
to 20.8; P=0.004) and 22.1% (95% CI 23.1 to 21.1; P,0.001)
in the TDF/FTC arm compared to 0.6% (95% CI 20.8 to 2.0;
P=0.400) and 0.3% (95% CI 20.9 to 1.6;P=0.594) in the ABC/
3TC arm. The percentage change from baseline in BMD was
significantly different between study arms both at week 24
(P=0.004 for hip and P=0.033 for lumbar spine) and week 48
(P=0.006 for hip and P=0.003 for lumbar spine). Similar results
were found for the absolute change in BMD in the two study arms
(fig. 2).
All biomarkers of bone turnover except OPG increased in the
TDF/FTC arm compared with the ABC/3TC arm (fig. 3). The
difference in change from baseline was statistically significant for
osteocalcin (P=0.004), P1NP (P,0.001), CTx (P=0.016), and
alkaline phosphatase (P=0.005) at week 48. At week 12 the
changes were significant for P1NP (P=0.005) and alkaline
phosphatase (P=0.003), but only for P1NP (P=0.009) at week
4. Contrary to this, OPG increased from baseline to week 4 in the
ABC/3TC arm compared with the TDF/FTC arm (P=0.029);
changes in OPG at week 12 and 48 were indifferent between study
arms. Using linear regression we explored the association between
early changes in bone turnover markers (baseline to 4 and 12
weeks, respectively) and subsequent reduction in BMD at week 48,
but found that none of the markers predicted BMD loss. In
addition, there were no association between baseline levels of bone
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females was slightly higher in the ABC/3TC arm we also checked
for any association between gender and change in BMD but found
none.
Markers of renal dysfunction
A decrease in eCrCl from baseline was observed in both study
arms that reached statistical significance at week 12, 24, and 48 in
the TDF/FTC arm, and at week 12 and 48 in the ABC/3TC arm.
In contrast, no significant change was observed from baseline to
week 48 in the plasma levels of cysC in any of the study arms.
There was no difference between study arms in the change from
baseline, neither in eCrCl nor plasma cysC at any time point
(fig. 4a and 4c). The changes from baseline in plasma phosphate
did not differ between study arms (data not shown). Changes in
urinary biomarkers were evaluated in 29 patients (15 in the TDF/
FTC arm and 14 in the ABC/3TC arm); of these, 24 were
followed from baseline to week 48. The urinary NGAL/creatinine
ratio increased in the TDF/FTC arm compared with the ABC/
3TC arm (P=0.047), but the difference was marginal (fig. 4).
There was a trend towards a similar increase in urinary cysC/
creatinine ratio (P=0.069) with TDF/FTC treatment compared
with ABC/3TC, whereas the change in albumin/creatinine ratio
was similar between study arms (P=0.695) (fig. 4).
There was no difference in blood pressure between study arms
at baseline or at the end of the study (data not shown).
Discussion
In this randomized clinical trial among virologically suppressed
HIV-infected adults, the introduction of fixed-dose treatment with
TDF/FTC lead to decreases in hip and lumbar spine BMD
compared with fixed-dose treatment with ABC/3TC. In addition,
we detected increases in the majority of measured bone turnover
biomarkers in TDF/FTC- compared with ABC/3TC-treated
patients. There was no difference in renal function between the
two study arms as evaluated by eCrCl or plasma cysC, but a minor
increase in urinary NGAL/creatinine ratio was observed in the
TDF/FTC arm compared with the ABC/3TC arm.
The strength of the study is the randomized design combined
with exploratory analyses of several biomarkers of bone and renal
function. Concurrent inflammation was assessed at baseline and
did not differ between study groups. Furthermore, the entry
criteria required that patients be negative for the HLAB5701
allele, had not previously been exposed to ABC or TDF, and had
been virologically suppressed for at least 3 months prior to
randomization.
Figure 1. Flow chart of inclusion and follow up.
doi:10.1371/journal.pone.0032445.g001
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evaluated BMD in virologically suppressed HIV-infected patients
switching to a TDF- or ABC-based regimen [14]. In the STEAL-
study TDF/FTC significantly lowered hip and spine T scores at
both weeks 48 and 96, whereas both T scores increased in the
ABC/3TC group. The changes in T scores in the two study arms
in our study were of a similar magnitude as in the STEAL-study
(data not shown). However, we used changes in BMD as the
principal bone endpoint measure and found reductions in BMD
with TDF/FTC-treatment, but stable rather than increased BMD
with ABC/3TC-treatment. Our patient material is much smaller
and, consequently, our data less robust. Biomarkers of bone
turnover increased in patients treated with TDF compared with
ABC in a recently presented STEAL-sub study, but early changes
in these biomarkers did not predict bone loss at week 96 [30]. We
measured bone turnover biomarker as early as 4 weeks after
randomization, which was not done in the STEAL-sub study, but
generally the changes seen in biomarkers of bone turnover in the
present study are in line with the findings of the STEAL- study. In
the SMART-study BMD declined more with continuous than
interrupted therapy, but no consistent drug-specific association
with BMD decline was found [31]. Bone turnover markers were
measured in an unpublished sub-study of the SMART study and
early changes (4 months after baseline) in some of these markers
predicted BMD changes over 12 months [32]. However, the
SMART-study was not designed to evaluate differences in BMD
between patients randomized to ABC- or TDF-based treatment
and is not directly comparable to our study. Two HAART-
initiation randomized trials of TDF versus ABC have evaluated
effects on BMD [11,13] in which BMD reductions with TDF
therapy were similar, or slightly larger, than in our material, but
comparison with these are not straightforward as decreases of
BMD have been observed with HAART-initiation irrespective of
regimen used [7–10,12].
Our results support the findings of previous studies [11,13,14]
that TDF treatment compared with ABC is associated with a
Table 1. Baseline characteristics.
Parameter TDF/FTC (n=20) ABC/3TC (n=20)
Anthropometric data
Mean age (95% CI), years 45.9 (41.8–49.9) 49.6 (44.0–55.1)
Male sex, n (%) 14 (70.0) 11 (55.0)
Active smokers, n (%) 9 (45.0) 6 (30.0)
Mean weight (95% CI), kg 74.9 (67.3–82.5) 73.2 (67.6–78.9)
Mean BMI (95% CI), kg/m
2 25.0 (23.0–27.0) 25.2 (24.2–26.1)
HIV-related data including HAART
Zidovudine/lamivudine at baseline, n (%) 20 (100) 20 (100)
PI at baseline, n (%) 6 (30.0) 6 (30.0)
Efavirenz at baseline, n (%) 9 (45.0) 11 (55.0)
Nevirapine at baseline, n (%) 5 (25.0) 3 (15.0)
Mean CD4+ cell count (95% CI), cells/mm
3, 540 (444–636) 567 (447–687)
Median duration of HAART exposure (IQR), years 8.9 (4.2–10.8) 7.2 (4.5–10.4)
Median time since HIV-diagnosis (IQR), years 10.2 (7.4–14.9) 10.6 (8.0–11.7)
Bone-related data
Mean lumbar spine BMD (95% CI), g/cm2 0.99 (0.93–1.04) 1.00 (0.95–1.05)
Mean hip BMD (95% CI), g/cm2 0.92 (0.86–0.98) 0.90 (0.84–0.97)
Median plasma osteocalcin (IQR), mikg/L 17.9 (15.3–22.5) 21.0 (17.5–27.2)
Median plasma P1NP (IQR), mikg/L 33.6 (29.8–48.2) 51.5 (33.8–62.6)
Median plasma CTx (IQR), ng/mL 0.25 (0.18–0.32) 0.34 (0.22–0.49)
Median plasma osteoprotegerin (IQR), pmol/L 3.4 (2.6–3.8) 3.1 (2.3–3.9)
Median plasma alkaline phosphatase (IQR), U/L 74.5 (65.5–90.5) 82.0 (68.5–99.5)
Renal function-related data
Mean systolic blood pressure (95% CI), mmHg 135 (127–142) 133 (122–143)
Mean diastolic blood pressure (95% CI), mmHg 84 (80–89) 85 (79–90)
Mean fasting plasma glucose (95% CI), mmol/L 5.4 (5.2–5.5) 5.4 (5.2–5.6)
Median eCrCl a.m. Cockcroft-Gault (IQR), mL/min 130 (118–140) 120 (92–154)
Median urine NGAL/creatinine ratio (IQR) 0.42 (0.08–1.72) 0.28 (0.00–0.71)
Median urine cystatin C/creatinine ratio (IQR) 0.92 (0.55–1.54) 1.05 (0.54–1.15)
Median urine albumine/creatinine ratio (IQR) 0.39 (0.23–0.88) 0.47 (0.32–1.20)
BMI=body mass index; PI=protease inhibitor; HAART=highly active antiretroviral therapy; HIV=human immunodeficiency virus; BMD=bone mass density;
P1NP=procollagen type 1 N-terminal propeptide; CTx=type I collagen cross-linked C-telopeptide; eCrCl=estimated creatinine clearance; NGAL=neutrophil gelatinase-
associated lipocalin. Normally distributed data are presented as means with 95% confidence interval (95% CI) in parenthesis. Skewed data are presented as medians
with interquartile range (IQR) in parenthesis.
doi:10.1371/journal.pone.0032445.t001
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this should be interpreted in the context of a normal reduction in
BMD after the age of 30 both in premenopausal women (,0.3%/
year), perimenopausal women (,1%/year), and men (0–0.5%/
year) [33]. Second, the loss of BMD is lesser than, but comparable
to the 2–10% reduction in lumbar spine BMD that is seen with
initiation of corticosteroids [34]. Still, initiation of corticosteroid
therapy is associated with an increase in incident fractures [34],
which has not been observed with initiation or switch to TDF-
based HIV-treatment [11,13,14,20], but studies so far have been
too small or too short to sufficiently address this issue.
Whether the observed changes in BMD in our study and those
of others are clinically relevant is a very interesting but difficult to
answer question. The observed loss of BMD is quite small and not
likely to confer a consequent increase in fracture risk in the
majority of HIV-infected patients. At least there is no data to
suggest that patients with higher risk of fractures should not receive
TDF, but alternatives may be considered for those with previous
fractures or known osteoporosis [35]. In addition, no increase in
risk of fracture among TDF-treated patients in the STEAL-study
was revealed with use of the FRAXH tool [30], but it should be
noted that the FRAXH tool is not validated for patients with BMD
reductions within the previous year.
It has been suggested that the initial loss of BMD may stabilize
after 1 year of treatment and therefore may be caused by a
continued effect of viral replication on bone turnover until
complete suppression, even though other explanations have also
been put forward [36]. Our data, and those of the STEAL-study,
indicate a direct effect of anti-retroviral therapy (ART) on bone
mass density. This is helpful in the efforts to understand how
traditional risk factors for low BMD, HIV-infection and ART each
contribute to the increased risk of low BMD and fractures among
HIV-infected individuals.
We measured several bone turnover markers to provide
additional information on the effects of these treatments on bone
remodeling and potentially the mechanisms underlying the
changes seen in BMD. Bone turnover markers increased in the
TDF/FTC arm within the first 12 weeks after treatment switch
and remained stably elevated hereafter. This indicate that loss of
BMD is associated with an increased rate of bone resorption and
formation that can be detected as early as 12 weeks after initiation
of TDF, and possibly already after 4 weeks. The early time point
evaluated in this study is particularly interesting, as comparable
studies have not provided data on bone turnover biomarkers so
shortly after treatment shift to a TDF-based regimen. Both OC
and OPG showed initial decreases in the TDF/FTC arm followed
by increase or stabilization, which raises the question if certain
signaling events relevant for the bone remodeling effects of TDF
are taking place within the first few weeks of treatment switch.
However, this remains speculative and the meaning of these
finding are uncertain. Whether the changes in markers of bone
turnover are reflecting direct effects of the treatment on the
osteoclasts or osteoblasts or both [37,38] or an indirect effect via
effects on the calcium homeostasis, including reduced activation of
vitamin D and secondary increases in parathyroid hormone,
remains to be shown [39]. It is also unclear whether these bone
turnover markers can be used for monitoring patients during
treatment as early changes in these markers did not predict BMD
loss similarly to what was observed in the STEAL sub-study [30].
We did not detect any differences between study arms in the
changes in eCrCl or plasma cysC, but still observed a minor
increase in 1 of 3 measured biomarkers of renal dysfunction
among patients in the TDF/FTC arm. This is comparable to the
findings in the HAART-initiation ASSERT-study [22] where
retinol-binding protein and b-2 microglobulin increased signifi-
cantly more in the TDF/FTC group. In other HAART-initiation
Figure 2. Changes from baseline in hip and lumbar spine BMD. Percentage and absolute mean changes from baseline in lumbar spine (a, c)
and hip (b, d) bone mass density as measured by dual energy x-ray absorptiometry (DXA). BMD=bone mass density; TDF/FTC=tenofovir/
emtricitabine; ABC/3TC=abacavir/lamivudine. Error bars show 95% confidence intervals.
doi:10.1371/journal.pone.0032445.g002
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e32445studies biochemical parameters of renal function were similar
between TDF/FTC and ABC/3TC treated patients [19–21], but
more patients in the TDF groups developed clinical renal
impairment [19,20]. No difference in eGFR, creatinine clearance
or other renal endpoints was found among virologically suppressed
HIV-patients in the STEAL-study [14].
The primary limitation of our study is the failure to reach the
intended number of enrolled patients, which reduced the statistical
power to detect differences between study arms. In addition, DXA
was not performed in all patients and we only have 48 weeks of
follow-up, which is too short to acknowledge the long-term effect
on BMD reductions that appear to occur primarily within the first
24–48 weeks with stabilization hereafter. Interestingly, while
Figure 3. Changes from baseline in biomarkers of bone turnover. Baseline levels of 25-OH vitamin D (a) and percentage changes from
baseline in biomarkers of bone turnover (b–f). P1NP=Procollagen type 1 N-terminal propeptide; CTx=Type I collagen cross-linked C-telopeptide
(CTx); OPG=Osteoprotegerin; TDF/FTC=tenofovir/emtricitabine; ABC/3TC=abacavir/lamivudine. Mean values are depicted for normally distributed
data and median values are depicted for skewed data. Accordingly, error bars show 95% confidence intervals or interquartile ranges.
doi:10.1371/journal.pone.0032445.g003
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plasma cysC was observed indicating a stable GFR. We did not
include GFR measurement by an exogenous marker and thus
cannot compare these two estimates with more precise GFR-
measurements. However, the eCrCl estimate based on plasma
creatinine is dependent on factors other than GFR, including
Figure 4. Changes from baseline in markers of impaired renal function. Changes from baseline to the indicated time points in estimated
creatinine clearance (a), levels of plasma cystatin C at baseline and week 48 (b), changes from baseline to week 48 in plasma cystatin C (c), and
changes from baseline to the last measurement in ratios of urinary biomarkers relative to urine creatinine concentration (d, e, f). Changes in urinary
biomarkers (d, e, f) were evaluated in 29 patients (15 in the TDF/FTC arm and 14 in the ABC/3TC arm); of these, 24 were followed from baseline to
week 48. Error bars in (a) show 95% confidence intervals; the horizontal line in (c) represents the mean value, while the horizontal lines in (d, e, f)
represent median values. eCrCl=estimated creatinine clearance; NGAL=neutrophil gelatinase-associated lipocalin TDF/FTC=tenofovir/emtricitabine;
ABC/3TC=abacavir/lamivudine.
doi:10.1371/journal.pone.0032445.g004
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e32445changes in muscle mass and tubular secretion of creatinine, and is
possible that either the HIV infection or the anti-viral treatment
may influence such factors. Previous studies comparing eCrCl and
cysC based GFR estimates on HIV patients with normal renal
function and on anti-viral treatment have generated mixed results
[40,41]. The 24-hour urine collections were not complete
precluding us from determining 24-hour excretion of albumin,
tubular markers, and the fractional phosphate excretion. Further-
more, due to incomplete sampling, urinary biomarkers were not
measured in all patients at all time points. We did not, however,
detect differences in plasma phosphate levels between study arms.
Long-term effects of HAART, including effects on bone and
renal function, will continue to be outcomes of interest in future
clinical trials. Beside this, more prospective studies will be needed
to evaluate potential interventions to prevent or reverse loss of
BMD. While several clinical trials have shown that bisphospho-
nate, vitamin D and calcium, either separate or in combination,
are safe and effective in the treatment of decreased BMD among
HIV-infected patients on HAART [42–45], there are still no
published studies on interventions to prevent bone loss associated
with TDF or HAART initiation.
In conclusion, we observed decreases in hip and lumbar spine
BMD, in conjunction with early increases in bone turnover
markers, in patients randomized to TDF/FTC-based treatment
compared with ABC/3TC. Changes in renal function were not
different between study arms although a very small increase in
NGAL was detected among TDF-treated patients. The clinical
significance of the latter is unclear.
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